BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Hematol. Nov 20, 2026; 12(3): 126171
Published online Nov 20, 2026. doi: 10.5315/wjh.126171
Table 1 Randomized controlled trials and pooled analysis of viscoelastic testing-guided transfusion in cirrhosis
Ref.
Design and sample size
Clinical setting
Assay
Transfusion outcome
Bleeding and mortality outcome
Rout et al[13]RCT, 30 vs 30, IndiaAcute variceal bleedingTEG4 patients (13.3%) vs all patients (100%) transfused, P < 0.001Rebleeding at 5 days 3.3% vs 13.3%, P = 0.167; rebleeding at 42 days 10.0% vs 36.7%, P = 0.012; 6-week mortality 13.3% vs 26.7%, P = 0.176
Kumar M et al[14]RCT, 49 vs 47, IndiaNonvariceal upper GI bleeding in advanced cirrhosisTEGAll three components (plasma, platelets, and cryoprecipitate) given to 26.5% vs 87.2%, P < 0.001Failure to control bleeding, rebleeding, and mortality similar in both arms
Vuyyuru et al[15]RCT, 29 vs 29, IndiaHigh-risk invasive liver-related proceduresTEG9 patients (31%) vs all patients (100%) transfusedNo procedure-related bleeding through 5 days in either arm
Biswas et al[16]RCT, three arms of 29, IndiaSevere thrombo­cytopenia before invasive proceduresTEGPlatelets: 4/29 (13.8%) with TEG, 29/29 (100%) with standard care, and 4/29 (13.8%) on demand; P < 0.001 for TEG vs standard careMinor bleeding in 3 (10%) with TEG vs 1 (3.4%) in each comparator arm, P = 0.43; no bleeding-related death
Kumar R et al[17]RCT, 20 vs 20, SingaporeElective procedures, predominantly low to intermediate riskROTEM40% vs 100% transfused, P < 0.001; less plasma, P < 0.001, and fewer platelets, P = 0.046No clinically significant bleeding; 30-day and 90-day mortality did not differ significantly
Hartmann et al[4]Meta-analysis of 5 earlier RCTs (302 patients)Cirrhosis, including liver transplantationTEGPlatelet use RR 0.17, 95%CI 0.03-0.90, P = 0.047-day mortality RR 0.52, 95%CI 0.30-0.91, P = 0.02
Table 2 Representative machine-learning models across the hemostatic spectrum in chronic liver disease
Ref.
Prediction target
Data modality
Model
Cohort
Reported performance
Validation design
Shung et al[18]Hospital-based intervention or death within 30 days in upper GI bleedingPresenting clinical and laboratory variablesGradient boosting1958 derivation across 4 countries; 399 geographic externalAUROC 0.91 internal and 0.90 external vs 0.88 and 0.87 for the Glasgow-Blatchford scoreGeographic external validation
Shung et al[19]Red cell transfusion, hemostatic intervention, or 30-day all-cause mortality in GI bleedingStructured EHR dataGradient boosting (XGBoost)2546 training; 850 internal; 926 geographic externalExternal AUROC 0.92, vs 0.89 for both Glasgow-Blatchford and Oakland scoresGeographic external validation
Wan et al[20]First variceal hemorrhage classification in a retrospective cohortCT angiography imagesVision trans­former plus reinforce­ment learning184 patients (107 with and 77 without first hemorrhage); random 7:3 splitAUROC 0.956 (95%CI 0.919-0.988) training; 0.985 (95%CI 0.955-1.000) validationRandom-split internal validation; no external cohort
Liu et al[21]Portal pressure gradient and high-risk portal hypertensionLaboratory and imaging variablesArtificial neural network428 patients with decompensated cirrhosis; 2 external datasetsReported accuracy 87.5%; external accuracy 85.4% and 90.8%; external AUROC 0.842 for high-risk portal hypertensionExternal validation in 2 datasets
Zheng et al[23]Rebleeding after endoscopic therapy in HBV cirrhosis with SPSSClinical and imaging featuresExtreme gradient boostingSPSS model cohorts: 153 development and 103 external; 77/153 and 68/103 rebleeds. Overall study populations: 295 and 190AUROC 0.814 (95%CI 0.785-0.843) internal; 0.776 (95%CI 0.748-0.805) externalProspective geographic external validation
Xiang et al[24]6-week treatment failure and 1-year mortality in acute variceal bleedingClinical data within 24 hours of admissionDeep learning1227 EVL-plus-drug patients: 668 training, 167 internal, 392 external. Separate p-TIPS treatment-stratification cohort: 1863AUROC 0.842 and 0.954 internal; 0.814 and 0.889 externalMulticenter external validation
Lian et al[25]Esophageal and esophagogastric variceal bleedingClinical, radiomic, and endoscopic inputsSystematic review and meta-analysis21 studies; 7011 patients; 1412 esophageal and 733 esophagogastric bleeding eventsPooled validation C-index 0.85 (95%CI 0.77-0.92) and 0.89 (95%CI 0.85-0.94), respectivelyPooled across heterogeneous studies
Li et al[29]Diagnosis of existing PVT in cirrhosisClinical, blood, and ultrasound variablesStacking ensemble468 development at the First Hospital of Lanzhou University; 348 external validation at Jilin Hepato-Biliary Diseases Hospital, Changchun, ChinaAUROC 0.73 development and 0.86 validationGeographic external validation
Meng et al[30]Portal vein thrombosis at 3 years and 5 years in HBV-related cirrhosisClinical and laboratory variablesArtificial neural networkDevelop­ment (2011-2014) and temporal validation (2015-2016) at the same hospital; cohort sizes are inconsistently reported in the sourceTemporal-validation AUROC 0.958 (95%CI 0.944-0.973) at 3 years and 0.973 (95%CI 0.958-0.987) at 5 yearsTemporal internal validation; no external site
Lou et al[37]Intraoperative red cell transfusion across surgical specialtiesPreoperative EHR dataGradient boosting (S-PATH)3275956 surgical cases at 45 United States hospitalsMedian AUROC 0.929 (IQR 0.915-0.946) vs 0.857 (IQR 0.822-0.884) for the maximum surgical blood order scheduleMulticenter external testing without local retraining


Write to the Help Desk